Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.63 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4576363 | 1.00 | OPRM1 (0.63) | OPRM1SLC6A2OPRD1 | |
| SCHEMBL30382471 | 0.93 | OPRM1 (0.67) | OPRM1SLC6A2OPRD1 | |
| SCHEMBL31410861 | 0.92 | OPRM1 (0.60) | OPRM1SLC6A2OPRD1 | |
| Lysine SCHEMBL185235 | 0.91 | OPRM1 (0.66) | OPRM1SLC6A2OPRD1 | |
| SCHEMBL29630405 | 0.90 | SLC6A2 (0.59) | OPRM1SLC6A2OPRD1 | |
| SCHEMBL31676579 | 0.90 | OPRM1 (0.63) | OPRM1SLC6A2OPRD1 | |
| SCHEMBL29713420 | 0.89 | SLC6A2 (0.62) | OPRM1SLC6A2OPRD1 | |
| SCHEMBL30423227 | 0.89 | OPRM1 (0.74) | OPRM1SLC6A2OPRD1 | |
| SCHEMBL29377141 | 0.89 | OPRM1 (0.61) | OPRM1SLC6A2OPRD1 | |
| SCHEMBL29571797 | 0.89 | OPRM1 (0.74) | OPRM1SLC6A2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1635872-A4 | ANTIBODIES AND FUSION PROTEINS THAT INCLUDE ENGINEERED CONSTANT REGIONS | ALEXION PHARMA INC (US) | 2008-01-02 | — | — | EP | claimed |
| EP-1635872-A2 | ANTIBODIES AND FUSION PROTEINS THAT INCLUDE ENGINEERED CONSTANT REGIONS | ALEXION PHARMACEUTICALS, INC. (US) | 2006-03-22 | — | — | EP | claimed |
| WO-2005007809-A2 | ANTIBODIES AND FUSION PROTEINS THAT INCLUDE ENGINEERED CONSTANT REGIONS | ALEXION PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | claimed |
| CN-115960168-A | Pearl peptide with multiple effects and preparation method and application thereof | 广东海洋大学 | 2023-04-14 | — | — | CN | disclosed |
| EP-1567541-A4 | RATIONALLY DESIGNED ANTIBODIES | ALEXION PHARMA INC (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1567541-A2 | RATIONALLY DESIGNED ANTIBODIES | ALEXION PHARMACEUTICALS, INC. (US) | 2005-08-31 | — | — | EP | disclosed |
| WO-2005060642-A2 | RATIONALLY DESIGNED ANTIBODIES | ALEXION PHARMACEUTICALS, INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2004108078-A2 | RATIONALLY DESIGNED ANTIBODIES | ALEXION PHARMACEUTICALS INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004050017-A2 | RATIONALLY DESIGNED ANTIBODIES | ALEXION PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| EP-1370589-A2 | RATIONALLY DESIGNED ANTIBODIES | ALEXION PHARMACEUTICALS, INC. (US) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002046238-A2 | RATIONALLY DESIGNED ANTIBODIES | ALEXION PHARMACEUTICALS, INC. (US) | 2002-06-13 | — | — | WO | disclosed |